Paxil CR For PMDD: FDA Decision Expected In “Coming Months,” GSK Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline expects to hear from FDA “in the coming months” on a pending premenstrual dysphoric disorder indication for its antidepressant Paxil CR.
You may also be interested in...
GSK Paxil CR PMDD approval
GlaxoSmithKline's selective serotonin reuptake inhibitor Paxil CR (paroxetine) clears FDA Aug. 28 for treatment of premenstrual dysphoric disorder, becoming the first controlled release antidepressant approved for PMDD. The other two approved PMDD therapies, Pfizer's Zoloft (sertraline) and Lilly's Sarafem (fluoxetine), are immediate release SSRI products. Paxil CR may have a dosing advantage over Zoloft, which can require titration when used for PMDD (1Pharmaceutical Approvals Monthly July 1, 2003, p. 11). The CR approval comes soon after the introduction of generic competition to immediate release Paxil; FDA cleared Apotex subsidiary TorPharm's generic version of IR Paxil July 30, but at least three other firms will share exclusivity. Synthon's mesylate-based formulation of paroxetine cleared FDA July 3 as a 505(b)2 NDA and will launch in the fourth quarter...
Paxil CR Vs. IR: GI Tolerability Claim Would Require Comparative Trials - FDA
A claim of superior GI tolerability for GlaxoSmithKline’s Paxil CR over immediate release Paxil would need to be supported by "carefully conducted studies that would compare the CR and IR forms at equieffective points on the dose response curves," FDA Psychiatric Drug Products Team Leader Thomas Laughren, MD, said in review documents for Paxil CR’s panic disorder indication.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011